Treatment of neovascular age-related macular degeneration with anti-vascular endothelial growth factor drugs: progress from mechanisms to clinical applications

被引:1
|
作者
Cheng, Shizhou [1 ]
Zhang, Shu [1 ]
Huang, Mingyan [1 ]
Liu, Yuxuan [1 ]
Zou, Xunyu [1 ]
Chen, Xiaoming [1 ]
Zhang, Zuhai [1 ]
机构
[1] Yangtze Univ, Dept Ophthalmol, Affiliated Hosp 1, Jingzhou, Peoples R China
关键词
neovascular age-related macular degeneration; vascular endothelial growth factor; treatment; mechanism; clinical application; INTRAVITREAL AFLIBERCEPT INJECTION; RANIBIZUMAB; THERAPY; VEGF; ANGIOGENESIS; OUTCOMES; PHARMACOKINETICS; CLASSIFICATION; DISCOVERY; HISTORY;
D O I
10.3389/fmed.2024.1411278
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Neovascular age-related macular degeneration (nARMD) is an important cause of visual impairment and blindness in the elderly, with choroidal neovascularization in the macula as the main pathological feature. The onset of nARMD is closely related to factors including age, oxidative stress, and lipid metabolism. Vascular endothelial growth factor (VEGF) is an important factor contributing to nARMD as well as choroidal neovascularization and retinal leakage formation. At present, anti-VEGF therapy is the only treatment that improves vision and halts disease progression in most patients, making anti-VEGF drugs a landmark development for nARMD treatment. Although intravitreal injection of anti-VEGF drugs has become the first-line treatment for nARMD, this treatment has many shortcomings including repeated injections, poor or no response in some patients, and complications such as retinal fibrosis. As a result, several new anti-VEGF drugs are being developed. This review provides a discussion of these new anti-VEGF drugs for the treatment of nARMD.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] LONG-TERM USE OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
    Begaj, Tedi
    Jeong, Daeun
    Park, Jong G.
    Runner, Margaret M.
    Capone, Antonio
    Dass, A. Bawa
    Drenser, Kimberly A.
    Faia, Lisa J.
    Farley, Nathan D.
    Garretson, Bruce R.
    Hassan, Tarek S.
    Mahmoud, Tamer H.
    Margherio, Alan
    Raphaelian, Paul V.
    Randhawa, Sandeep
    Ruby, Alan J.
    Sneed, Scott
    Rao, Prethy
    Wolfe, Jeremy D.
    Williams, George A.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2024, 44 (02): : 222 - 229
  • [32] Quarterly Anti-Vascular Endothelial Growth Factor Dosing for Neovascular Age-Related Macular Degeneration: Real-World Clinical Outcomes
    Rusakevich, Alexander M.
    Zhou, Brenda
    Wong, Tien P.
    Wykoff, Charles C.
    OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2019, 50 (09) : E250 - E256
  • [33] THE EFFECT OF NICOTINE ON ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN A MOUSE MODEL OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
    Davis, Stephen J.
    Lyzogubov, Valeriy V.
    Tytarenko, Ruslana G.
    Safar, Ammar N.
    Bora, Nalini S.
    Bora, Puran S.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2012, 32 (06): : 1171 - 1180
  • [34] Caregiver Experience Survey of Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration
    Viola, Francesco
    Chi, Gloria C.
    Holekamp, Nancy M.
    Giocanti-Auregan, Audrey
    Garcia-Layana, Alfredo
    Peto, Tunde
    Kertes, Peter J.
    Mirt, Mirela
    Kotecha, Aachal
    Lambert, Jeremy
    Lewis, Hannah B.
    Gentile, Brittany
    OPHTHALMIC RESEARCH, 2024, 67 (01) : 516 - 527
  • [35] MACULAR ATROPHY INCIDENCE IN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR-TREATED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION Risk Factor Evaluation for Individualized Treatment Need of Ranibizumab or Aflibercept According to an Observe-and-Plan Regimen
    Mantel, Irmela
    Dirani, Ali
    Zola, Marta
    Parvin, Parmis
    De Massougnes, Sophie
    Bergin, Ciara
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2019, 39 (05): : 906 - 917
  • [36] Patient Experience Survey of Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
    Holekamp, Nancy
    Gentile, Brittany
    Giocanti-Auregan, Audrey
    Garcia-Layana, Alfredo
    Peto, Tunde
    Viola, Francesco
    Kertes, Peter J.
    Mirt, Mirela
    Kotecha, Aachal
    Lambert, Jeremy
    Lewis, Hannah B.
    Chi, Gloria C.
    OPHTHALMIC RESEARCH, 2024, 67 (01) : 311 - 321
  • [37] Defining Nonadherence and Nonpersistence to Anti-Vascular Endothelial Growth Factor Therapies in Neovascular Age-Related Macular Degeneration
    Okada, Mali
    Wong, Tien Yin
    Mitchell, Paul
    Eldem, Bora
    Talks, S. James
    Aslam, Tariq
    Daien, Vincent
    Rodriguez, Francisco J.
    Gale, Richard
    Barratt, Jane
    Finger, Robert P.
    Loewenstein, Anat
    JAMA OPHTHALMOLOGY, 2021, 139 (07) : 769 - 776
  • [38] Effects of delay in anti-vascular endothelial growth factor intravitreal injections for neovascular age-related macular degeneration
    Hanhart, Joel
    Wiener, Rony
    Totah, Hashem
    Gelman, Evgeny
    Weill, Yishay
    Abulafia, Adi
    Zadok, David
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2022, 260 (06) : 1907 - 1914
  • [39] Switching Anti-Vascular Endothelial Growth Factors in Refractory Neovascular Age-Related Macular Degeneration
    Ashraf, Mohammed
    Banaee, Touka
    Silva, Fabiana Q.
    Singh, Rishi P.
    OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2018, 49 (03) : 166 - +
  • [40] Aflibercept anti-vascular endothelial growth factor therapy in vitrectomized eyes with neovascular age-related macular degeneration
    Jung, Jesse J.
    Hoang, Quan V.
    Arain, Mohammad Z. Y.
    Chang, Stanley
    ACTA OPHTHALMOLOGICA, 2016, 94 (03) : E249 - E250